Clinical Trial Detail

NCT ID NCT02213289
Title PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors University of Chicago
Indications

gastroesophageal junction adenocarcinoma

gastric adenocarcinoma

Therapies

Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab

Docetaxel + Fluorouracil

Trastuzumab

Fluorouracil + Irinotecan + Leucovorin

Rilotumumab

Age Groups: adult

No variant requirements are available.